Fig. 1 | British Journal of Cancer

Fig. 1

From: Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

Fig. 1

Trial profile depicting the total number of patients at screening, inclusion, randomisation, and analysis. FLOT 5-fluorouracil, leucovorin, oxaliplatin and docetaxel, i.p. intraperitoneal, pts patients. *one patinet did not receive at least one dose of catumaxomab and was switched to the FLOT arm (for safety population only). +one patient died after three doses of catumaxomab and did not receive FLOT treatment

Back to article page